Jiangtang Decoction Ameliorates Diabetic Kidney Disease Through the Modulation of the Gut Microbiota

References

• Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ. 2017;356:i6505. doi:10.1136/bmj.i6505
   PubMed Web of Science ®Google Scholar
• Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788. doi:10.1016/S0140-6736(18)32203-7
   PubMed Web of Science ®Google Scholar
• Zhang L, Long J, Jiang W, et al. Trends in Chronic Kidney Disease in China. N Engl J Med. 2016;375(9):905–906. doi:10.1056/NEJMc1602469
   PubMed Web of Science ®Google Scholar
• Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5(1):49–56.
   PubMedGoogle Scholar
• Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010;268(5):456–467. doi:10.1111/j.1365-2796.2010.02269.x
   PubMed Web of Science ®Google Scholar
• Kopel J, Pena-Hernandez C, Nugent K. Evolving spectrum of diabetic nephropathy. World J Diabetes. 2019;10(5):269–279. doi:10.4239/wjd.v10.i5.269
   PubMed Web of Science ®Google Scholar
• Arora MK, Singh UK. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update. Vascul Pharmacol. 2013;58(4):259–271. doi:10.1016/j.vph.2013.01.001
   PubMed Web of Science ®Google Scholar
• Rayego-Mateos S, Morgado-Pascual JL, Opazo-Rios L, et al. Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. Int J Mol Sci. 2020;21(11):3798. doi:10.3390/ijms21113798
   PubMed Web of Science ®Google Scholar
• Maiti AK. Development of biomarkers and molecular therapy based on inflammatory genes in diabetic nephropathy. Int J Mol Sci. 2021;22(18):9985. doi:10.3390/ijms22189985
   PubMed Web of Science ®Google Scholar
• Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol. 2016;12(1):13–26. doi:10.1038/nrneph.2015.175
   PubMed Web of Science ®Google Scholar
• Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol. 2005;16(Suppl 1):S30–S33. doi:10.1681/ASN.2004110970
   PubMed Web of Science ®Google Scholar
• Niewczas MA, Pavkov ME, Skupien J, et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med. 2019;25(5):805–813. doi:10.1038/s41591-019-0415-5
   PubMed Web of Science ®Google Scholar
• Lavoz C, Rayego-Mateos S, Orejudo M, et al. Could IL-17A be a novel therapeutic target in diabetic nephropathy? J Clin Med. 2020;9(1):272. doi:10.3390/jcm9010272
   PubMed Web of Science ®Google Scholar
• Fathy SA, Mohamed MR, Ali M, El-Helaly AE, Alattar AT. Influence of IL-6, IL-10, IFN-gamma and TNF-alpha genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients. Biomarkers. 2019;24(1):43–55. doi:10.1080/1354750X.2018.1501761
   PubMed Web of Science ®Google Scholar
• Dixit VD. Nlrp3 inflammasome activation in type 2 diabetes: is it clinically relevant? Diabetes. 2013;62(1):22–24. doi:10.2337/db12-1115
   PubMed Web of Science ®Google Scholar
• Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int. 2013;83(6):1010–1016. doi:10.1038/ki.2012.440
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Yuan J, Nazertehrani S, Ni Z, Liu S. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol. 2013;38(2):99–103. doi:10.1159/000353764
   PubMed Web of Science ®Google Scholar
• Jiang S, Xie S, Lv D, et al. Alteration of the gut microbiota in Chinese population with chronic kidney disease. Sci Rep. 2017;7(1):2870. doi:10.1038/s41598-017-02989-2
   PubMed Web of Science ®Google Scholar
• Xu KY, Xia GH, Lu JQ, et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci Rep. 2017;7(1):1445. doi:10.1038/s41598-017-01387-y
   PubMed Web of Science ®Google Scholar
• Kanbay M, Onal EM, Afsar B, et al. The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus. Int Urol Nephrol. 2018;50(8):1453–1466. doi:10.1007/s11255-018-1873-2
   PubMed Web of Science ®Google Scholar
• Salguero MV, Al-Obaide M, Singh R, Siepmann T, Vasylyeva TL. Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease. Exp Ther Med. 2019;18(5):3461–3469. doi:10.3892/etm.2019.7943
   PubMed Web of Science ®Google Scholar
• Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25(4):657–670. doi:10.1681/ASN.2013080905
   PubMed Web of Science ®Google Scholar
• Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–455. doi:10.1161/CIRCRESAHA.116.305360
   PubMed Web of Science ®Google Scholar
• Hong JN, Li WW, Wang LL, et al. Jiangtang decoction ameliorate diabetic nephropathy through the regulation of PI3K/Akt-mediated NF-kappaB pathways in KK-Ay mice. Chin Med. 2017;12(1):13. doi:10.1186/s13020-017-0134-0
   PubMedGoogle Scholar
• Hong JN, Li WW, Fu H, Wang XM. 中药降糖复方水提取物对KK-Ay糖尿病小鼠糖基化终末端产物及氧化应激的影响 [Study on effect of Jiangtang decoction on AGEs-RAGE and oxidative stress in KK-Ay mice]. Zhongguo Zhong Yao Za Zhi. 2017;42(14):2754–2759. Chinese. doi:10.19540/j.cnki.cjcmm.20170609.007
   PubMedGoogle Scholar
• Sun H, Liu Q, Hu H, et al. Berberine ameliorates blockade of autophagic flux in the liver by regulating cholesterol metabolism and inhibiting COX2-prostaglandin synthesis. Cell Death Dis. 2018;9(8):824. doi:10.1038/s41419-018-0890-5
   PubMedGoogle Scholar
• Gong P, Xiao X, Wang S, et al. Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway. J Ethnopharmacol. 2021;281:114558. doi:10.1016/j.jep.2021.114558
   PubMed Web of Science ®Google Scholar
• Liu C, Zhao D, Ma W, et al. Denitrifying sulfide removal process on high-salinity wastewaters in the presence of Halomonas sp. Appl Microbiol Biotechnol. 2016;100(3):1421–1426. doi:10.1007/s00253-015-7039-6
   PubMed Web of Science ®Google Scholar
• Chen S, Zhou Y, Chen Y, Gu J. FASTP: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884–i890. doi:10.1093/bioinformatics/bty560
   PubMed Web of Science ®Google Scholar
• Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011;27(21):2957–2963. doi:10.1093/bioinformatics/btr507
   PubMed Web of Science ®Google Scholar
• Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–583. doi:10.1038/nmeth.3869
   PubMed Web of Science ®Google Scholar
• Bolyen E, Rideout JRDillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nature Biotechnology. 2019;37(2):852–857. doi:10.1038/s41587-019-0209-9
   PubMedGoogle Scholar
• Schloss P D, Westcott S LRyabin T, et al. Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities. Appl Environ Microbiol. 2009;75(2):7537 doi:10.1128/AEM.01541-09
   PubMedGoogle Scholar
• Jung CY, Yoo TH. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. Diabetes Metab J. 2022;46(2):181–197. doi:10.4093/dmj.2021.0329
   PubMed Web of Science ®Google Scholar
• Cao T, Xu R, Xu Y, Liu Y, Qi D, Wan Q. The protective effect of Cordycepin on diabetic nephropathy through autophagy induction in vivo and in vitro. Int Urol Nephrol. 2019;51(10):1883–1892. doi:10.1007/s11255-019-02241-y
   PubMed Web of Science ®Google Scholar
• Hathaway CK, Gasim AM, Grant R, et al. Low TGFbeta1 expression prevents and high expression exacerbates diabetic nephropathy in mice. Proc Natl Acad Sci U S A. 2015;112(18):5815–5820. doi:10.1073/pnas.1504777112
   PubMed Web of Science ®Google Scholar
• Cai TT, Ye XL, Li RR, et al. Resveratrol modulates the gut microbiota and inflammation to protect against diabetic nephropathy in mice. Front Pharmacol. 2020;11:1249. doi:10.3389/fphar.2020.01249
   PubMed Web of Science ®Google Scholar
• Lim AK, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, Tesch GH. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia. 2009;52(8):1669–1679. doi:10.1007/s00125-009-1399-3
   PubMed Web of Science ®Google Scholar
• Wu M, Han W, Song S, et al. NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice. Mol Cell Endocrinol. 2018;478:115–125. doi:10.1016/j.mce.2018.08.002
   PubMed Web of Science ®Google Scholar
• Kuo HL, Huang CC, Lin TY, Lin CY. IL-17 and CD40 ligand synergistically stimulate the chronicity of diabetic nephropathy. Nephrol Dial Transplant. 2018;33(2):248–256. doi:10.1093/ndt/gfw397
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Saigusa D, Kanemitsu Y, et al. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun. 2019;10(1):1835. doi:10.1038/s41467-019-09735-4
   PubMedGoogle Scholar
• Mosterd CM, Kanbay M, van den Born B, van Raalte DH, Rampanelli E. Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression. Best Pract Res Clin Endocrinol Metab. 2021;35(3):101484. doi:10.1016/j.beem.2021.101484
   PubMed Web of Science ®Google Scholar
• Gryp T, Huys G, Joossens M, Van Biesen W, Glorieux G, Vaneechoutte M. Isolation and quantification of uremic toxin precursor-generating gut bacteria in chronic kidney disease patients. Int J Mol Sci. 2020;21(6):1986. doi:10.3390/ijms21061986
   PubMed Web of Science ®Google Scholar
• Chen L, Shi J, Ma X, Shi D, Qu H. Effects of microbiota-driven therapy on circulating indoxyl sulfate and P-cresyl sulfate in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr. 2022;13(4):1267–1278. doi:10.1093/advances/nmab149
   PubMed Web of Science ®Google Scholar
• Zhu W, Romano KA, Li L, et al. Gut microbes impact stroke severity via the trimethylamine N-oxide pathway. Cell Host Microbe. 2021;29(7):1199–1208. doi:10.1016/j.chom.2021.05.002
   PubMed Web of Science ®Google Scholar
• Pelletier CC, Croyal M, Ene L, et al. Elevation of trimethylamine-N-Oxide in chronic kidney disease: contribution of decreased glomerular filtration rate. Toxins. 2019;11(11):635. doi:10.3390/toxins11110635
   PubMed Web of Science ®Google Scholar
• Gruppen EG, Garcia E, Connelly MA, et al. TMAO is associated with mortality: impact of modestly impaired renal function. Sci Rep. 2017;7(1):13781. doi:10.1038/s41598-017-13739-9
   PubMedGoogle Scholar
• Sun G, Yin Z, Liu N, et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity. Biochem Biophys Res Commun. 2017;493(2):964–970. doi:10.1016/j.bbrc.2017.09.108
   PubMed Web of Science ®Google Scholar
• Chang JF, Hsieh CY, Lu KC, et al. Therapeutic targeting of aristolochic acid induced uremic toxin retention, SMAD 2/3 and JNK/ERK pathways in tubulointerstitial fibrosis: nephroprotective role of propolis in chronic kidney disease. Toxins. 2020;12(6):364. doi:10.3390/toxins12060364
   PubMed Web of Science ®Google Scholar
• Koppe L, Pillon NJ, Vella RE, et al. p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol. 2013;24(1):88–99. doi:10.1681/ASN.2012050503
   PubMed Web of Science ®Google Scholar
• Deltombe O, Van Biesen W, Glorieux G, Massy Z, Dhondt A, Eloot S. Exploring protein binding of uremic toxins in patients with different stages of chronic kidney disease and during hemodialysis. Toxins. 2015;7(10):3933–3946. doi:10.3390/toxins7103933
   PubMed Web of Science ®Google Scholar
• Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat Rev Nephrol. 2018;14(7):442–456. doi:10.1038/s41581-018-0018-2
   PubMed Web of Science ®Google Scholar
• Andersen K, Kesper MS, Marschner JA, et al. Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. J Am Soc Nephrol. 2017;28(1):76–83. doi:10.1681/ASN.2015111285
   PubMed Web of Science ®Google Scholar
• Meehan CJ, Beiko RG. A phylogenomic view of ecological specialization in the Lachnospiraceae, a family of digestive tract-associated bacteria. Genome Biol Evol. 2014;6(3):703–713. doi:10.1093/gbe/evu050
   PubMed Web of Science ®Google Scholar
• Zhou Q, Yang F, Li Z, et al. Paecilomyces cicadae-fermented Radix astragali ameliorate diabetic nephropathy in mice by modulating the gut microbiota. J Med Microbiol. 2022;71(5). doi:10.1099/jmm.0.001535
   Web of Science ®Google Scholar
• Chen W, Zhang M, Guo Y, et al. The profile and function of gut microbiota in diabetic nephropathy. Diabetes Metab Syndr Obes. 2021;14:4283–4296. doi:10.2147/DMSO.S320169
   PubMed Web of Science ®Google Scholar
• Zhang W, Jiang S, Qian D, Shang EX, Duan JA. Analysis of interaction property of calycosin-7-O-beta-D-glucoside with human gut microbiota. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;963:16–23. doi:10.1016/j.jchromb.2014.05.015
   PubMed Web of Science ®Google Scholar
• Ruan JQ, Li S, Li YP, Wu WJ, Lee SM, Yan R. The presystemic interplay between gut microbiota and orally administered Calycosin-7-O-beta-D-Glucoside. Drug Metab Dispos. 2015;43(10):1601–1611. doi:10.1124/dmd.115.065094
   PubMed Web of Science ®Google Scholar
• Li L, Li R, Zhu R, et al. Salvianolic acid B prevents body weight gain and regulates gut microbiota and LPS/TLR4 signaling pathway in high-fat diet-induced obese mice. Food Funct. 2020;11(10):8743–8756. doi:10.1039/D0FO01116A
   PubMed Web of Science ®Google Scholar
• Bai Y, Bao X, Mu Q, et al. Ginsenoside Rb1, salvianolic acid B and their combination modulate gut microbiota and improve glucolipid metabolism in high-fat diet induced obese mice. Peerj. 2021;9:e10598. doi:10.7717/peerj.10598
   PubMed Web of Science ®Google Scholar
• Lyu Y, Lin L, Xie Y, et al. Blood-glucose-lowering effect of coptidis rhizoma extracts from different origins via gut microbiota modulation in db/db mice. Front Pharmacol. 2021;12:684358. doi:10.3389/fphar.2021.684358
   PubMed Web of Science ®Google Scholar
• Dong GM, Yu H, Pan LB, et al. Biotransformation of timosaponin BII into seven characteristic metabolites by the gut microbiota. Molecules. 2021;26(13):3861. doi:10.3390/molecules26133861
   PubMed Web of Science ®Google Scholar
• China TSPC. Pharmacopoeia of the People’s Republic of China. 2020 ed. Beijing: China Medical Science Press; 2022.
   Google Scholar